Patients 1000 patients aged > 25 years (mean age 49 y, 90% men) with ≥ 1 major risk factor for CAD (hypercholesterolaemia, hypertension, diabetes mellitus, angina pectoris, or previous myocardial infarction [MI]). Exclusion criteria included cancer, chronic diarrhoea or dysentery, blood urea concentrations > 6.6 mmol/l, arthritis, dislike of the intervention diet, and refusal of laboratory test...

Although left ventricular (LV) systolic dysfunction in patients suffering from Takayasu arteritis (TA) has been reported, little is known regarding the development of heart failure in these patients. We report a novel finding of active TA and familial hypercholesterolaemia presenting with severe LV dysfunction through multimodality assessments of LV systolic dysfunction.

See page 465 for the article to which this Editorial refers The current extensive interest in research of infectious disease or, more generally, participation of the immune response in the pathogenesis of coronary atherosclerosis may partly be as a result of the role played by traditional risk factors in this disease. Although there is no doubt the multifactorial atherogenic process includes nu...

As part of its single technology appraisal (STA) process, the UK National Institute for Health and Care Excellence (NICE) invited the manufacturer of evolocumab (Amgen) to submit evidence on the clinical and cost effectiveness of evolocumab. The appraisal assessed evolocumab as monotherapy or in combination with a statin with or without ezetimibe, or in combination with ezetimibe (without stati...

Dear Sirs, The term “aspirin resistance” (1) has been used to describe a number of different phenomena, including inability of aspirin to: (i) protect against cardiovascular events despite its regular intake; (ii) to affect various laboratory tests, reflecting platelet activity. Indeed, there is a good evidence to indicate that there are subpopulations which do not respond to antithrombotic act...

OBJECTIVE To assess acute tissue plasminogen activator (t-PA) release in vivo in patients with hypercholesterolaemia in the presence and absence of lipid lowering treatment and in matched normocholesterolaemic controls. DESIGN Parallel group comparison and double blind randomised crossover. SETTING University hospital. PATIENTS Eight patients with hypercholesterolaemia (> 7.8 mmol/l) and ...